FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900689096> ?p ?o ?g. }

• W2900689096 endingPage "136" @default.
• W2900689096 startingPage "1" @default.
• W2900689096 abstract "Background Depression is usually managed in primary care and antidepressants are often the first-line treatment, but only half of those treated respond to a single antidepressant. Objectives To investigate whether or not combining mirtazapine with serotonin–noradrenaline reuptake inhibitor (SNRI) or selective serotonin reuptake inhibitor (SSRI) antidepressants results in better patient outcomes and more efficient NHS care than SNRI or SSRI therapy alone in treatment-resistant depression (TRD). Design The MIR trial was a two-parallel-group, multicentre, pragmatic, placebo-controlled randomised trial with allocation at the level of the individual. Setting Participants were recruited from primary care in Bristol, Exeter, Hull/York and Manchester/Keele. Participants Eligible participants were aged ≥ 18 years; were taking a SSRI or a SNRI antidepressant for at least 6 weeks at an adequate dose; scored ≥ 14 points on the Beck Depression Inventory-II (BDI-II); were adherent to medication; and met the International Statistical Classification of Diseases and Related Health Problems , Tenth Revision, criteria for depression. Interventions Participants were randomised using a computer-generated code to either oral mirtazapine or a matched placebo, starting at a dose of 15 mg daily for 2 weeks and increasing to 30 mg daily for up to 12 months, in addition to their usual antidepressant. Participants, their general practitioners (GPs) and the research team were blind to the allocation. Main outcome measures The primary outcome was depression symptoms at 12 weeks post randomisation compared with baseline, measured as a continuous variable using the BDI-II. Secondary outcomes (at 12, 24 and 52 weeks) included response, remission of depression, change in anxiety symptoms, adverse events (AEs), quality of life, adherence to medication, health and social care use and cost-effectiveness. Outcomes were analysed on an intention-to-treat basis. A qualitative study explored patients’ views and experiences of managing depression and GPs’ views on prescribing a second antidepressant. Results There were 480 patients randomised to the trial (mirtazapine and usual care, n = 241; placebo and usual care, n = 239), of whom 431 patients (89.8%) were followed up at 12 weeks. BDI-II scores at 12 weeks were lower in the mirtazapine group than the placebo group after adjustment for baseline BDI-II score and minimisation and stratification variables [difference –1.83 points, 95% confidence interval (CI) –3.92 to 0.27 points; p = 0.087]. This was smaller than the minimum clinically important difference and the CI included the null. The difference became smaller at subsequent time points (24 weeks: –0.85 points, 95% CI –3.12 to 1.43 points; 12 months: 0.17 points, 95% CI –2.13 to 2.46 points). More participants in the mirtazapine group withdrew from the trial medication, citing mild AEs (46 vs. 9 participants). Conclusions This study did not find convincing evidence of a clinically important benefit for mirtazapine in addition to a SSRI or a SNRI antidepressant over placebo in primary care patients with TRD. There was no evidence that the addition of mirtazapine was a cost-effective use of NHS resources. GPs and patients were concerned about adding an additional antidepressant. Limitations Voluntary unblinding for participants after the primary outcome at 12 weeks made interpretation of longer-term outcomes more difficult. Future work Treatment-resistant depression remains an area of important, unmet need, with limited evidence of effective treatments. Promising interventions include augmentation with atypical antipsychotics and treatment using transcranial magnetic stimulation. Trial registration Current Controlled Trials ISRCTN06653773; EudraCT number 2012-000090-23. Funding This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 22, No. 63. See the NIHR Journals Library website for further project information." @default.
• W2900689096 created "2018-11-29" @default.
• W2900689096 creator A5019176918 @default.
• W2900689096 creator A5026519715 @default.
• W2900689096 creator A5027143609 @default.
• W2900689096 creator A5027494774 @default.
• W2900689096 creator A5034780845 @default.
• W2900689096 creator A5036427315 @default.
• W2900689096 creator A5048461202 @default.
• W2900689096 creator A5048785509 @default.
• W2900689096 creator A5049834363 @default.
• W2900689096 creator A5054449436 @default.
• W2900689096 creator A5055543220 @default.
• W2900689096 creator A5069618968 @default.
• W2900689096 creator A5070418920 @default.
• W2900689096 creator A5078660144 @default.
• W2900689096 creator A5079346001 @default.
• W2900689096 creator A5079429053 @default.
• W2900689096 date "2018-11-01" @default.
• W2900689096 modified "2023-10-12" @default.
• W2900689096 title "Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT" @default.
• W2900689096 cites W1851357683 @default.
• W2900689096 cites W1969640133 @default.
• W2900689096 cites W1979281142 @default.
• W2900689096 cites W1986039176 @default.
• W2900689096 cites W1990166011 @default.
• W2900689096 cites W1997191720 @default.
• W2900689096 cites W2014236381 @default.
• W2900689096 cites W2015700432 @default.
• W2900689096 cites W2016460740 @default.
• W2900689096 cites W2017663874 @default.
• W2900689096 cites W2018642794 @default.
• W2900689096 cites W2020804995 @default.
• W2900689096 cites W2031756259 @default.
• W2900689096 cites W2033726468 @default.
• W2900689096 cites W2043705607 @default.
• W2900689096 cites W2047582412 @default.
• W2900689096 cites W2049103906 @default.
• W2900689096 cites W2059908520 @default.
• W2900689096 cites W2068630143 @default.
• W2900689096 cites W2074056096 @default.
• W2900689096 cites W2096304631 @default.
• W2900689096 cites W2098974730 @default.
• W2900689096 cites W2102656145 @default.
• W2900689096 cites W2104518967 @default.
• W2900689096 cites W2110608362 @default.
• W2900689096 cites W2113559481 @default.
• W2900689096 cites W2114613490 @default.
• W2900689096 cites W2115343912 @default.
• W2900689096 cites W2115504852 @default.
• W2900689096 cites W2120698260 @default.
• W2900689096 cites W2127841934 @default.
• W2900689096 cites W2128283668 @default.
• W2900689096 cites W2132322340 @default.
• W2900689096 cites W2136228108 @default.
• W2900689096 cites W2138218422 @default.
• W2900689096 cites W2140815719 @default.
• W2900689096 cites W2145618858 @default.
• W2900689096 cites W2146322264 @default.
• W2900689096 cites W2147581820 @default.
• W2900689096 cites W2148801257 @default.
• W2900689096 cites W2149402043 @default.
• W2900689096 cites W2151590183 @default.
• W2900689096 cites W2155959499 @default.
• W2900689096 cites W2158318448 @default.
• W2900689096 cites W2167165853 @default.
• W2900689096 cites W2167710208 @default.
• W2900689096 cites W2172151487 @default.
• W2900689096 cites W2178666919 @default.
• W2900689096 cites W2225684373 @default.
• W2900689096 cites W2254646458 @default.
• W2900689096 cites W2319463639 @default.
• W2900689096 cites W2513524236 @default.
• W2900689096 cites W2516321587 @default.
• W2900689096 cites W2525291061 @default.
• W2900689096 cites W2529744628 @default.
• W2900689096 cites W2541285986 @default.
• W2900689096 cites W2765219543 @default.
• W2900689096 cites W4231622706 @default.
• W2900689096 cites W4251784043 @default.
• W2900689096 doi "https://doi.org/10.3310/hta22630" @default.
• W2900689096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6287172" @default.
• W2900689096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30468145" @default.
• W2900689096 hasPublicationYear "2018" @default.
• W2900689096 type Work @default.
• W2900689096 sameAs 2900689096 @default.
• W2900689096 citedByCount "21" @default.
• W2900689096 countsByYear W29006890962019 @default.
• W2900689096 countsByYear W29006890962020 @default.
• W2900689096 countsByYear W29006890962021 @default.
• W2900689096 countsByYear W29006890962022 @default.
• W2900689096 countsByYear W29006890962023 @default.
• W2900689096 crossrefType "journal-article" @default.
• W2900689096 hasAuthorship W2900689096A5019176918 @default.
• W2900689096 hasAuthorship W2900689096A5026519715 @default.
• W2900689096 hasAuthorship W2900689096A5027143609 @default.
• W2900689096 hasAuthorship W2900689096A5027494774 @default.
• W2900689096 hasAuthorship W2900689096A5034780845 @default.

• next